Friedman-Klabanoff DJ, Berry AA, Travassos MA, Cox C, et al. Low dose recombinant full-length circumsporozoite protein-based Plasmodium
falciparum vaccine is well-tolerated and highly immunogenic in phase 1
first-in-human clinical testing. Vaccine 2021 Jan 22. pii: S0264-410X(20)31590.
PMID: 33494963